Resting natural killer (NK) cells express the p75 chain of the IL-2 receptor (IL-2R beta) and most NK cells express the CD2 (erythrocyte rosette) receptor. The cell adhesion molecule, LFA-3, is a natural co-ligand for CD2. Tac antigen (IL-2R alpha), a p55 IL-2R subunit, can be expressed after NK activation and may play a role in IL-2-induced NK proliferation. Little is known of the molecular mechanisms underlying cytokine production in NK cells. We investigated the roles of IL-2R alpha, IL-2R beta, and CD2/LFA-3 in the molecular regulation of NK cell granulocyte/macrophage-colony-stimulating factor (GM-CSF) production. Enriched populations of peripheral blood NK cells were separated into CD16-positive and CD16-negative fractions by flow cytometry; positively selected cells were greater than 97% positive for CD16 (the FcIII receptor for IgG which is present on almost all NK cells), less than 1% positive for the T cell antigen CD3, and did not demonstrate rearrangement of the T cell receptor beta chain gene by Southern blot. NK cell supernatants were harvested after 3-4 d of incubation with 0-100 U/ml IL-2, or after incubation with anti-CD2 (T11(3] MAb and sheep red blood cells (SRBC are a homologue for LFA-3). Parallel cell aliquots were harvested at 3-16 h for transcriptional run-on assays, S1 nuclease assays, and actinomycin D mRNA t1/2 determinations. IL-2-activated NK supernatants contained large amounts of […] tants were harvested after 3-4 d of incubation with 0-100 U/ml IL-2, or after incubation with anti-CD2 (T113) MAb and sheep red blood cells (SRBC are a homologue for LFA-3). Parallel cell aliquots were harvested at 3-16 h for transcriptional run-on assays, S1 nuclease assays, and actinomycin D mRNA t1/2 determinations. IL-2-activated NK supernatants contained large amounts of GM-CSF (178±35 pg/ml) by ELISA as did supernatants from CD2-activated NK cells (T113 MAb + SRBC: 212±42) vs. < 20 pg/ml for NK cells incubated alone or with either SRBC or T113 MAb alone. Sepharose-linked anti-CD3 MAb did not induce GM-CSF release from NK cells. By S1 analysis, both IL-2 and CD2 stimulation markedly augmented GM-CSF mRNA expression but with very different latencies of onset. IL-2R,6 MAb inhibited > 85% of GM-CSF release from IL-2-activated NK cells and markedly suppressed IL-2-induced GM-CSF mRNA expression, whereas IL-2Ra MAb even at 2,000-fold molar excess of IL-2 had little effect (< 10%) on either GM-CSF release or mRNA expression. Run-on assays showed that GM-CSF is constitutively transcribed in NK cells and that IL-2 and CD2-activated cells had a three-to fourfold increased rate of GM-CSF transcription compared to nonstimulated cells. The t1/2 of GM-CSF mRNA in IL-2-actiAddress reprint requests to Dr. Levitt, Room S-161, Hematology Division,
The dimeric receptor consists of both IL-2Ra and IL-2Rf3 and binds IL-2 with high affinity (Kd 10-12) (3) (4) (5) . Resting NK cells constitutively express the IL-2R# chain of the IL-2 receptor and do not express the IL-2Ra subunit; IL-2Ra is expressed after NK activation and plays a role in IL-2-induced NK proliferation (6) (7) (8) .
Another antigen which is expressed on > 80% NK cells is the CD2 (erythrocyte rosette) receptor (9) . The CD2 receptor is also expressed on all T cells and thymocytes and appears to serve as an antigen-independent pathway ofT lymphocyte activation (10) . Combinations of anti-CD2 antibodies can stimulate T cell proliferation (10) . The cell surface molecule lymphocyte function-associated antigen-3 (LFA-3) is a natural co-ligand for CD2 and, in combination with a single anti-CD2 antibody, is also capable ofenhancing T cell proliferation (1 1). Cellular activation with a combination of anti-CD2 monoclonal antibodies (MAbs) has recently been shown to enhance cytotoxicity ofNK cells against otherwise resistant targets ( 12).
NK cells have been shown to stimulate both myeloid and erythroid colony growth (13) (14) (15) (16) . However, in most of these studies the cytokine mediating such stimulatory activity has not been identified and interpretation of results is complicated by heterogeneity ofthe cell populations assessed. Additionally, cloned human NK cell lines have been reported not to release humoral factors promoting hematopoietic colony growth (17) . Cuturi et al. (18) have recently demonstrated that highly purified populations of NK cells can produce granulocyte/macrophage-colony-stimulating factor (GM-CSF), a cytokine with potent hematopoietic stimulatory activity both in vitro and in vivo (18) .
Little is known about the molecular mechanisms underlying cytokine expression in NK cells or the potential ofNK CD2 or IL-2 surface receptors to modulate cytokine production. We asked whether NK cells are capable ofproducing GM-CSF and assessed the roles of IL-2Ra, IL-2R,3, and CD2/LFA-3 in the molecular regulation of NK cell GM-CSF production.
Methods
Blood and marrow samples. Peripheral blood and bone marrow aspirates were obtained from normal, healthy adult donors after informed consent. All protocols were approved by the Stanford Medical Committee for the Use of Human Subjects in Research. Blood and marrow samples were diluted in medium and layered over Ficoll-Hypaque gradients (density, 1.077 g/cm3), and mononuclear cells at the interface were collected after washing and centrifugation.
Monoclonal antibodies and cytokines. T lymphocyte MAbs antiLeu-l (CD5), anti-Leu-2a (CD8), anti-Leu-3a (CD4), and anti-Leu-4 (CD3) were all purchased from Becton, Dickinson & Co., Mountain View, CA. OKT3 MAb (Ortho Pharmaceuticals, Raritan, NJ) (CD3) is a pan-T cell MAb; in some experiments OKT3 was used after linking to cyanogen Br-Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ) according to published methods (19) . Anti-Leu-12 (Becton, Dickinson & Co.) (CD19) and anti-B 1 (Coulter Corp., Hialeah, FL) (CD20) are both pan-B lymphocyte MAbs. Anti-Leu-M3 (Becton, Dickinson & Co.) (CD14) is a monocyte MAb. Anti-Leu-11 ( (22) . We used cytofluorographic analysis in three independent experiments to assess the ability ofTU27 to block biotinylated IL-2 binding to IL-2R,8 on resting NK cells. TU27 and IL-2 bound separately to > 95% ofpurified NKcells; Tu27 MAb suppressed IL-2 binding to < 5% whereas isotype control MAb had no effect on IL-2 binding.
YTA-1 is an IgG, MAb (Dr. Yodoi, Tohoku University, Kyoto) which also reacts with a p75 subunit of the IL-2R but does not inhibit IL-2 binding (23). Anti-TI 13 MAb recognizes an epitope of the CD2 receptor and was generously provided by E. Reinherz (Dana Farber Cancer Center, Boston, MA) (10). Anti-IL-3 is an IgG, MAb (Genzyme Corp., Boston, MA) which is > 95% pure by HPLC and demonstrates no reactivity against GM-CSF, IL-2 or IL-4. 500 jig ofanti-IL-3 completely neutralizes 2,500 U (25 ng) ofhuman IL-3. Anti-GM-CSF is also an IgG, MAb (Genzyme Corp.) which is > 95% pure and demonstrates no reactivity against IL-3 or granulocyte-colony-stimulating factor (G-CSF). 1 Ag of anti-GM-CSF completely neutralizes 50 U of recombinant GM-CSF. Recombinant IL-2 (4.2 X 109 U/g protein) was generously provided by Cetus Corp., Emeryville, CA and was > 98% pure by HPLC. Recombinant GM-CSF and IL-3 were both purchased from Genzyme Corp. (24) . CD16-positive cells were > 98% positive for Leu II (CD16) and < 1% positive for Leu-4 (CD3) or Leu-5 (CD1). As previously demonstrated, essentially all peripheral blood-derived cytotoxicity against the NK-sensitive K562 cell line was mediated by CD16-positive cells (24) . Additionally, Eco RI-digested genomic DNA from CDI6-positive cells was assessed by southern blot analysis after hybridization with 32P-labeled C, cDNA derived from the T cell receptor ft chain gene. The Eco RI restriction enzyme pattern of CD16-positive cells demonstrated a germline configuration (i.e., two distinct fragments of 10 and 4 kb) identical to that of granulocytes whereas CD16-negative cells, which are > 99% positive for the pan-T antigen CD3, demonstrated an altered pattern of DNA fragments compatible with multiple individual rearrangements within a polyclonal population ofT lymphocytes (24) . The density ratio ofthe 10-kb fragment to the 4-kb fragment in CDI6-positive cells (1: 1) was identical to the ratio in granulocytes.
In some experiments, NK cells were purified by indirect methods utilizing the techniques ofsolid-phase immunoabsorption and immunomagnetic separation. Enriched [7, 25] ).
In some experiments NK cells were cultured with the CD2 MAb anti- added to each well and plates were incubated for 2 h at 37°C. I00-MI dilutions ofrecombinant GM-CSF standard and test samples were then added before incubation for 1 h at 37°C. Wells were washed four times with Tween 20 buffer and blotted, and 100 Ml of rabbit anti-human GM-CSF antibody was then added to each well. Plates were incubated again for 1 h at 37°C and blotted before the addition of 100 Ml of biotin-conjugated goat anti-rabbit antibody to each well. After incubation for 45 min at 37°C, plates were washed and blotted before addition of avidin-peroxidase (100 Ml per well). After a 40-min incubation at 37°C, 100 Al of O-phenylenediamine substrate with peroxide was added. The plates were developed for 5 min at 23°C and the reaction was halted with 100 Ml of 1 M H2SO4. Absorbance was measured at 492 nm with an ELISA reader. Sensitivity ofthe assay was 20 pg/ml and no cross-reactivity exists in the assay for IL-3, G-CSF, macrophage-colony-stimulating factor (M-CSF), IL-6, interferon-y (IFN-,y), or tumor necrosis factor-alpha (TNF-a).
RNA extraction and nuclease SI protection assay. Total cellular RNA was isolated using a guanidinium thiocyanate-phenol-chloroform extraction procedure (28) . RNA samples were quantitated by spectrophotometric analysis at 260 and 280-nm. Parallel RNA aliquots were visualized on ethidium bromide-stained 1.2% agarose-formaldehyde gels to assess integrity ofRNA and to verify sample amounts. The 5-prime end-labeled NcoI linearized fragment of GM-CSF cDNA clone 3-8a was hybridized with jo0-Mg samples oftotal RNA in 15 Ml ofa solution containing 80% redistilled formamide, 0.4 M NaCl, I mM EDTA, and 50 mM PIPES (pH 6.4) at 50°C (29, 30) . Split aliquots of RNA were similarly hybridized with the 5-prime end-labeled Hinfl-linearized fragment of human cytoskeletal #-actin clone pHFPA-l (31) .
After 6 h of incubation, 150 Ml of cold SI digestion buffer containing 200 U/ml Sl nuclease (Boehringer-Mannheim Biochemicals, Indianapolis, IN), 250 mM NaCl, 30 mM NaAc, and 1 mM ZnCl was added to the hybridization mixture and incubated at 37°C for 45 min (30) . Samples were transferred to an ice bath for 10 min, 10 g of carrier tRNA was added and the Sl-resistant hybrids were precipitated by 2 vol of ethanol. Pellets were washed, dried, and resuspended in 10 Ml formamide and dye before fractionation on a 5% polyacrylamide gel containing 7 M urea, with subsequent autoradiography. Autoradiograms were scanned by laser densitometry. Negative controls consisting of labeled cDNA with carrier transfer RNA in the absence oftest samples were utilized in each experiment. Labeled cDNA was also hybridized to 6 gg oftotal cellular RNA derived either from the human T lymphotropic virus-II-infected Mo T cell line (positive control) or from the colon adenocarcinoma cell line A7C (negative control). In some experiments, unstimulated NK cells and cells exposed to either IL-2 or CD2 MAb plus SRBC for 6 h were cultured with actinomycin D (5 Mg/ml) for 5-120 min before RNA harvest. induce GM-CSF release (125-179 pg/ml) from purified peripheral blood T lymphocytes. Expression of GM-CSF mRNA was next assessed in nonstimulated and activated NK cells using a nuclease SI protection assay (Fig. 1) . The protected cDNA which complexed with GM-CSF mRNA is indicated by the arrow at 600 bp. Split RNA aliquots were also hybridized to labeled cDNA for /3-actin as a control to ensure that comparable amounts of RNA were in each lane (bands at 450 bp). Small amounts of GM-CSF transcript were detectable in NK cells incubated in media alone and by densitometry remained quantitatively unchanged for 1-15 h of incubation. No band at 600 bp was seen in the negative control lane (GM-CSF probe hybridized to RNA from a colon adenocarcinoma cell line). The kinetics of GM-CSF expression after either IL-2 or CD2 stimulation were quite different. Augmented expression of GM-CSF mRNA was first observed 6 h after stimulation of NK cells with 100 U/ml IL-2, whereas augmented GM-CSF transcript was noted as early as 1 h after NK activation with anti-Tl 13 MAb plus SRBC. A Sepharose-linked anti-CD3 MAb (OKT3) (10 gg/ml) did not augment NK cell GM-CSF mRNA compared to resting NK cells (not shown).
Effect ofIL-2-or CD2-activated NKcells on marrow hematopoietic colony formation. Supernatants derived from either IL-2-or CD2-activated NK cells caused potent stimulation of BFU-E grown from NAB-T marrow (Table II) , compared to supernatants from resting NK cells or from NK cells incubated singly with either anti-T 113 MAb or SRBC. Supernatants from IL-2-and CD2-activated NK cells also caused potent stimulation of marrow CFU-GM (data not shown).
IL-2 stimulated NK cells to augment erythropoiesis in a dose-dependent manner (Fig. 2) . Marked stimulation was observed in the range of 100 pM to 1 nM (-10-100 U/ml). These IL-2 concentrations are consistent with those concentrations needed to bind the isolated IL-2RB subunit of the IL-2 receptor (7).
The addition ofanti-GM-CSF MAb to IL-2-or CD2-activated NK cell supernatants suppressed 84-95% of observed BFU-E stimulation (Table II) . In control experiments, identical amounts of anti-GM-CSF MAb inhibited > 96% of erythroid colony growth induced by 40 pg/ml of human recombinant GM-CSF yet had virtually no effect on erythroid colony growth induced by human IL-3. Anti-IL-3 MAb had no effect on erythroid stimulation induced by IL-2-or CD2-activated MAb (YTA-1) which fails to block IL-2 binding to the IL-2R also had no effect on GM-CSF release from IL-2-activated NK cells. Anti-IL-2Ra MAb (Tac-1, 67 nM), which markedly suppresses IL-2-induced proliferation of T cells bearing the highaffinity IL-2R, had little effect (< 11%) on GM-CSF release from IL-2-activated NK cells (Table III) . Concentrations of anti-IL-2Ra MAb, even when used in 2,000-fold molar excess ofIL-2, had no additional effect on GM-CSF release. The combination ofanti-IL-2R/3 (Tu27) plus anti-IL-2Ra MAbs had a very small additional effect on GM-CSF release relative to the suppression observed with anti-IL-2Rf MAb alone.
Preincubation with anti-IL-2R3 MAb (Tu27) also markedly suppressed (78-91%) the ability of IL-2-activated NK cells to stimulate marrow BFU-E and CFU-GM, whereas the anti-p75 control MAb (YTA-1) or an anti-IL-2Ra MAb (Tac-1) had little discernable effect on NK cell-mediated augmentation of colony growth (data not shown).
We next assessed modulation of NK cell GM-CSF mRNA expression by IL-2Ra and IL-2Rfi MAbs. RNA was extracted from FACS-purified NK cells and hybridized with labeled GM-CSF cDNA (Fig. 3) 2-induced GM-CSF mRNA expression whereas anti-IL-2Ra MAb (Tac-l, 670 nM) had little effect on expression of GM-CSF mRNA. Concentrations ofanti-IL-2Rac MAb, when used in 2,000-fold molar excess of IL-2, had no additional effect on GM-CSF mRNA expression (data not shown). A negative control consisting of the labeled cDNA mixed with carrier RNA alone is also indicated in Fig. 3 (-CON) whereas a positive control consisting of labeled cDNA mixed with cellular RNA from a HTLV-II-infected T cell line (Mo) displayed a strong GM-CSF mRNA signal (+CON, Fig. 3 ). An anti-p75 control MAb (YTA-1) (10 ug/ml) had no discernable effect on GM-CSF mRNA expression from IL-2-activated NK cells. In a separate series of three experiments, RNA was extracted from NK cells purified by negative selection (using solid-phase immunoabsorption and immunomagnetic separation) and GM-CSF mRNA expression again assessed by S1 protection assay. GM-CSF mRNA was again observed in resting NK cells purified by negative selection; IL-2 (100 U/ml) strongly augmented GM-CSF mRNA expression (data not shown). Preincubation with anti-IL-2R,3 MAb virtually abrogated IL-2-induced GM-CSF mRNA expression.
Mechanism of augmented GM-CSF expression in stimulated NK cells. Increased levels of GM-CSF mRNA after IL-2 or CD2 activation of NK cells could result from an increased rate of transcription or enhanced stabilization of GM-CSF transcripts which appear to be constitutively expressed in NK cells. To assess possible posttranscriptional regulation of GM-CSF transcripts, unstimulated and activated NK cells were cultured with actinomycin D (5 jg/ml) for 5-120 min. RNA was harvested and examined for GM-CSF mRNA levels by S1 assay (Fig. 4) . The protected GM-CSF bands are indicated in the upper portion of the figure where the numbered lanes correspond to 0-120 min of actinomycin D exposure. Autoradiograms were scanned by laser densitometry and mRNA stability was plotted in the lower portion of the figure. The t/2 of GM-CSF mRNA in IL-2-activated NK cells was virtually identical to that of unstimulated NK cells (15 min), whereas GM-CSF mRNA tl/2 in CD2-activated NK cells was increased 2.0-2.5-fold in three separate experiments. Neither IL-2 nor CD2 stimulation had any detectable effect on NK cell fl-actin mRNA t1/2 over 12 h of actinomycin D exposure; this result is consistent with earlier observations concerning actin mRNA tl/2 in stimulated T cells (32) . Calculated GM-CSF mRNA t/2's were identical when densitometric values were normalized for ,B-actin expression.
Transcriptional regulation of NK cell GM-CSF expression was next assessed using an in vitro nuclear run-on assay. In this assay, transcripts were generated by elongation of previously initiated mRNA chains during incubation of isolated nuclei in the presence of [32P]UTP. The membrane on the left of Fig. 5 was hybridized to nuclear RNA from CD2-activated NK cells, the center membrane was hybridized to RNA from nonstimulated NK cells, and the membrane on the right was hybridized to RNA from IL-2-activated NK cells. GM-CSF is constitutively transcribed at a low level in nonstimulated NK cells. IL-2 and CD2-activated NK cells demonstrate by densitometry a three-to fourfold increased rate ofGM-CSF transcription compared to nonstimulated cells. Similar results were obtained in three independent run-on experiments. Nonstimulated and activated NK cells show equal rates ofB-actin transcription ( negative control immobilized strands (cardiac promotor actin, tRNA and pBR322 plasmid DNA) (Fig. 5) . The mean incorporations of [32P]UTP in unstimulated and activated NK cells were nearly equal. In additional, control experiments, the membranes were heated to remove NK cell nuclear RNA and reprobed with labeled nuclear RNA from a C32 melanoma cell line; C32 RNA did not hybridize to the immobilized GM-CSF 72 Levitt et al. (38) . Three NK cell cytokines (TNF, IFN--y, and GM-CSF) are each capable of enhancing peripheral blood phagocytic activity and augmenting microbicidal capacity (33, 39, 40) . NK (42) . IL-I also appears to enhance cytokine mRNA stability in fibroblasts, perhaps via the induction of an inhibitor which blocks ribonuclease-induced degradation of cytokine mRNA (43) . GM-CSF has been shown to be constitutively transcribed in human fibroblasts and in human T cells immortalized with HTLV-1, but does not appear to be expressed constitutively in primary human T cells (42, 44, 45) . Very little is known about cytokine regulation in human NK cells. Our results indicate that GM-CSF in NK cells is constitutively transcribed at low levels and that both IL-2 and CD2 stimulation markedly enhance NK cell GM-CSF rates of transcription. CD2 but not IL-2 stimulation also appears to modestly enhance GM-CSF mRNA stability; it is likely, however, that transcriptional stimulation rather than enhanced mRNA stability is largely responsible for CD2-induced augmentation of GM-CSF production in NK cells. It is possible that GM-CSF transcription in nonstimulated NK cells reflects inadvertent cellular activation during the process of purification. However, this possibility seems unlikely for at least three reasons. First, purified NK cells demonstrated no cytotoxic activity against NK-resistant target cells (the colon carcinoma line COLO) even at E/T ratios of 15:1 whereas activated NK cells readily kill this cell line. Secondly, purified nonstimulated NK cells did not demonstrate proliferative activity whereas activated NK cells readily incorporate [3H]thymidine (7) . Thirdly, purified nonstimulated NK cells did not express the activation antigens CD25 (IL-2Ra) or CD7 1 (transferrin receptor) whereas the majority of activated NK cells express these antigens.
IL-2R,# is preferentially expressed on resting human peripheral blood NK cells (6) (7) (8) . It has also been identified in the absence of Tac antigen (IL-2Ra) on the surface of small numbers ofresting T cells and some B cells (46) . Increasing evidence suggests that IL-2R(# is capable of mediating signal transduction (46, 47) . '25I-IL-2 chemical crosslinking and 121I-IL-2 radioreceptor binding assays in the presence and absence of antiTac MAb have indirectly suggested that IL-2 binding to IL2Rf may mediate at least the initial phases ofNK cell cytolysis and proliferation as well as the early induction of lymphokineactivated killer (LAK) activity (6) (7) (8) . The recent production of anti-p75 MAbs which block IL-2 binding to IL-2R,3 now make it possible to more directly assess the function and biologic role of IL-2RB in IL-2-mediated cellular activation and cytokine production (22, 48) . Our studies indicate that anti-IL-2RB MAb specifically inhibits GM-CSF release from IL-2-activated NK cells, blocks the ability of IL-2-activated NK cells to augment hematopoietic colony growth and markedly suppresses IL-2-induced GM-CSF mRNA expression. Anti-Tac MAb, which directly blocks IL-2 binding to IL-2Ra and inhibits IL-2-dependent proliferation ofT lymphocytes, has little effect on NK cell GM-CSF release or mRNA expression, even when used in 2,000-fold molar excess of IL-2. Additionally, the IL-2 concentrations (100 pM to 1 nM) that optimally stimulate NK cell augmentation of erythroid colony growth (Fig. 2) are consistent with those concentrations needed to bind IL-2RB. Highaffinity IL-2Rs are nearly saturated at 100 pM and the isolated IL-2Ra subunit is minimally occupied at 100 pM (7) . Taken together, these data strongly suggest that IL-2RB is the molecule most directly responsible for IL-2 activation of NK cell GM-CSF production. Together with previous reports, the data suggest that IL-2 binding to IL-2R(3 may mediate not only NK cell cytolysis and the initial phases of NK cell proliferation but may also play an important role in NK cell cytokine production.
Cellular activation with a combination of anti-CD2 MAbs has been shown to enhance cytotoxicity of NK cell clones against otherwise resistant targets and to enhance the cytolytic function of fresh peripheral blood NK cells (9, 12) . Similar anti-CD2 MAb combinations can also induce T cell proliferation; recently, binding of an LFA-3 homologue (SRBC) to T cells has been shown to induce reactivity to otherwise submitogenic concentrations ofanti-CD2 MAbs (1 1). Our studies indicate that SRBC in combination with a single anti-CD2 MAb are capable of enhancing NK cell GM-CSF production even though each ligand alone has a negligible effect on cytokine production. These results suggest that, in addition to IL-2R3, CD2 membrane receptors are also capable of modulating NK cell GM-CSF production and that one of the signals required for NK cell activation through the CD2 pathway is provided by the interaction of CD2 with its naturally occurring co-ligand, i.e., LFA-3. These data also imply that several distinct mechanisms may well be capable ofenhancing NK cell cytokine production.
